Description

Letrozol CRCA Coated Tablets 2.5 mg. №30

Ingredients

Each tablet contains 2.5 mg of Letrozole.

Dosage

The recommended dosage is one 2.5 mg tablet daily, or as directed by a healthcare professional.

Indications

Letrozol CRCA tablets are indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women.

Contraindications

Do not use Letrozol CRCA tablets if you are pregnant, breastfeeding, or allergic to Letrozole.

Directions

Swallow the tablet whole with a glass of water, with or without food, at the same time each day.

Scientific Evidence

Letrozole, the active ingredient in Letrozol CRCA tablets, is an aromatase inhibitor that works by reducing the production of estrogen in the body. This inhibition of estrogen synthesis is crucial in the treatment of hormone receptor-positive breast cancer. Clinical studies have shown that Letrozole is effective in improving disease-free survival and reducing the risk of cancer recurrence compared to tamoxifen.

Additional Information

Letrozol CRCA tablets have been well-studied in various clinical trials, demonstrating their efficacy and safety profile. These tablets offer a convenient once-daily dosing regimen, enhancing patient compliance and treatment outcomes. It is important to follow the prescribed dosage and consult with a healthcare provider for personalized guidance during treatment.